NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Want to cut your energy bills? Here’s how five experts are doing it 
NEW YORK, March 02, 2017 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Aratana Therapeutics, Inc. securities (NASDAQ:PETX) from March 16, 2015 through February 3, 2017, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aratana investors under the federal securities laws.
To join the Aratana class action, go to http://rosenlegal.com/cases-1049.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Aratana did not have manufacturing contracts in place sufficient to support manufacturing of ENTYCE at a commercial scale; (2) consequently, ENTYCE was not likely to be commercially available until late 2017; (3) accordingly, Aratana had misled investors with respect to the likely timeline for a commercial launch of ENTYCE; and (4) as a result, Aratana’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1049.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com
